Table 4 Novel oncogenic kinase and other small molecule inhibitors in R/R PTCL

Dasatinib

SRC kinase

Phase I/II, 9

56%

22%

PFS 2.5 months

OS 4.5 months

[125]

Dasatinib

SRC kinase

Phase I, 4

100%

0%

-

[126]

Duvelisib

PI3K-δ/γ

Phase I, 16

50%

19%

PFS 8.3 months

OS 8.4 months

[128]

Duvelisib

PI3K-δ/γ

Phase II, 101

49%

34%

PFS 1.5–9.1 months

OS 4.8–15.5 months

[129]

Copanlisib

PI3K-α/δ

Phase II, 14

21%

14%

-

[130]

Linperlisib

PI3K-δ

Phase Ib, 43

60%

35%

PFS 10 months

12-month OS 77%

[131]

Linperlisib

PI3K-δ

Phase II, 88

48%

30%

PFS 5.5 months

OS 14.2 months

[132]

BR101801

PI3Kγ/δ/DNA-PK

Phase I, 19

32%

21%

PFS 7.5 months

[133]

Duvelisib plus Romidepsin

PI3K/HDAC

Phase Ib, 48

56%

44%

PFS 6.8 months

[134]

Tenalisib plus Romidepsin

PI3K/HDAC

Phase I/II, 16

75%

26%

-

[135]

Copanlisib plus gemcitabine

PI3K

Phase I/II, 25

72%

32%

PFS 6.9 months

OS not reached

[136]

Ruxolitinib

JAK1/2

Phase II, 45

27%

7%

PFS 2.8 months

OS 26.2 months

[137]

Cerdulatinib (ALXN2075)

SYK/JAK

Phase II, 58

36%

21%

PFS 4.6 months (AITL/TFL)

[138]

Golidocitinib (AZD4205)

JAK1

Phase II, 104

44%

24%

PFS 5.6 months

OS 19.4 months

[139]

Alisertib

AURKA

Phase II, 8

50%

-

-

[140]

Alisertib

AURKA

Phase II, 30

30%

7%

-

[141]

Alisertib

AURKA

Phase III, 271

33%

18%

PFS 3.8 months

OS 13.7 months

[142]

Bortezomib plus Panobinostat

Proteasome/HDAC

Phase II, 23

43%

22%

-

[143]

Ixazomib

Proteasome

Phase I, 4

25%

0%

-

[145]

Ixazomib

Proteasome

Phase II, 7

14%

14%

-

[146]

Selinexor (ATG-010)

XPO1

Phase I, 2

50%

0%

-

[147]

Selinexor plus ICE

XPO1

Phase I, 10

100%

90%

1-year OS 67%

[148]

Selinexor plus GEMOX

XPO1

Phase Ib, 17

53%

35%

PFS 2.9 months

6-month OS 69%

[149]

Tipifarnib

Farnesyltransferase

Phase II, 42

52%

24%

OS 32.8 months (AITL)

[150]

Forodesine

PNP

Phase I/II, 41

25%

10%

PFS 1.9 months

OS 15.6 months

[152]